Futura Medical is at an exciting juncture, with pivotal Eroxon® data due by mid-2016 and EU filings of TPR100 & TIB200 targeted for the end of the year. Regulatory approval of the change in manufacturing process for CSD500 (enabling a longer shelf life) is also expected this year. We have adopted a more conservative stance on the CSD500 rollout through partners, incl. first significant revenue in 2017e (from 2016).
05 Apr 2016
Eroxon® data ahead
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Eroxon® data ahead
Futura Medical plc (FUM:LON) | 35.7 -0.1 (-0.6%) | Mkt Cap: 107.7m
- Published:
05 Apr 2016 -
Author:
N+1 Singer Team -
Pages:
4
Futura Medical is at an exciting juncture, with pivotal Eroxon® data due by mid-2016 and EU filings of TPR100 & TIB200 targeted for the end of the year. Regulatory approval of the change in manufacturing process for CSD500 (enabling a longer shelf life) is also expected this year. We have adopted a more conservative stance on the CSD500 rollout through partners, incl. first significant revenue in 2017e (from 2016).